Results 231 to 240 of about 85,787 (336)

Microbiota in pancreatic ductal adenocarcinoma progression and therapy: The hidden players. [PDF]

Chin Med J (Engl)
Hu X, Kong F, Chen J, Li Z, Cai Z, Kong X.   +5 more
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, Volume 13, Issue 17, 23 March 2026.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

Peripheral immune landscape in pancreatic ductal adenocarcinoma reveals expansion of effector states with disease progression. [PDF]

iScience
Yang CH, Lung YY, Chen CC, Lo IH, Lien CJ, Wu WK, Wu MS, Liao WC, Lin JD.   +8 more
europepmc   +1 more source

Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer

Advanced Science, Volume 13, Issue 16, 18 March 2026.
This study demonstrates that dual UCP2/IL‐17 blockade reprograms T‐cell metabolism to overcome PDAC immunosuppression. Genipin‐mediated UCP2 inhibition enhances CD8⁺ T‐cell IFN‐γ via IL‐12R/STAT4/mTOR signaling and mitochondrial OXPHOS. Combined IL‐17 depletion amplifies Tc1/Th1 responses, reduces MDSCs, and prolongs survival in PDAC models ...
Chuan‐Teng Liu, Chun‐Chieh Yeh, Tsai‐Chen Wu, Chia‐Hsin Lin, Yi‐Ting Kuo, Yoichiro Iwakura, Yuan‐Ji Day, Charles Drake, Vedran Radojcic, Ying‐Chyi Song, Heng‐Hsiung Wu, Hung‐Rong Yen   +11 more
wiley   +1 more source

AUM-302, a novel triple PIM/PI3K/mTOR inhibitor, synergizes with RAS inhibition and impedes the growth of pancreatic ductal adenocarcinoma spheroids and organoids. [PDF]

Front Pharmacol
Wen E, Vera C, Kesavan S, Kouassi F, LaComb JF, Zand N, Tuveson DA, Habowski AN, Baines AT, Bialkowska AB.   +9 more
europepmc   +1 more source

Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer

Advanced Science, Volume 13, Issue 17, 23 March 2026.
Mutant p53 drives oncogenic splicing to promote the progression of ovarian cancer by partnering with the spliceosome factor SNRPD2. Therefore, it is engineered iRGD‐exosomes to co‐deliver siRNAs against both targets. This approach restored tumor‐suppressive mRNA isoforms, effectively enhanced sensitivity to cisplatin, and ultimately blocked tumor ...
Wei Zhao, Qian Hao, Yu Gan, Jing Tong, Xiaodan Chen, Shuran Tan, Ruiwen Ruan, Yingdan Huang, Mingming Cao, Jun Deng, Tao Han, Getao Shi, Bo Gao, Yu Zhang, Xiang Zhou   +14 more
wiley   +1 more source

Mitophagy in pancreatic cancer: mechanistic insights and implications for novel therapeutic strategies. [PDF]

Cell Death Discov
Wang Z, Lyu Z, Palmen R, Bao Q, Popp F, Dong Q, Bruns CJ, Zhao Y.   +7 more
europepmc   +1 more source

SiCmiR Atlas: Single‐Cell miRNA Landscape Reveals Hub‐miRNA and Network Signatures in Human Cancers

Advanced Science, Volume 13, Issue 16, 18 March 2026.
SiCmiR predicts mature miRNA activity at single‐cell resolution using only 977 landmark genes, enabling scalable reconstruction of miRNA landscapes across diverse tissues and disease contexts. The SiCmiR Atlas integrates 9.36 million cells with analytical tools for hub‐miRNA discovery, biomarker prioritization, and regulatory network interrogation ...
Xiao‐Xuan Cai, Jing‐Shan Liao, Jia‐Jun Ma, Yu‐Xuan Pang, Yi‐Gang Chen, Yang‐Chi‐Dung Lin, Yi‐Dan Chen, Xin Cao, Yi‐Cheng Zhang, Tao‐Sheng Xu, Tzong‐Yi Lee, Hsi‐Yuan Huang, Hsien‐Da Huang   +12 more
wiley   +1 more source

Ellagic acid is associated with reduced pancreatic carcinogenesis and modulation of the IL-6/STAT3 pathway. [PDF]

Genes Environ
Kato H, Naiki-Ito A, Komura M, Nagayasu Y, Sato M, Kuang X, Nagano A, Takahashi S.   +7 more
europepmc   +1 more source

KRAS dosage key in PDAC [PDF]

Nature Reviews Gastroenterology & Hepatology, 2018
openaire   +1 more source